Amneal Pharmaceuticals(AMRX) - 2025 Q1 - Quarterly Results

Exhibit 99.1 AMNEAL REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS ‒ Q1 2025 Net Revenue of $695 million; GAAP Net Income of$12 million; Diluted Income per Share of $0.04 ‒ ‒ Adjusted EBITDA of$170 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Af irming 2025 Full Year Guidance ‒ BRIDGEWATER, NJ, May 2, 2025 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced its results for the first quarter ended March 31, 2025. "Amneal delivered another strong quarter to start 2025, with ...